A Balanced Look at the Promising Yet Controversial Anti-Amyloid Drugs: Lecanemab and Donanemab

Published by Alison Watson-Shields on

In recent years, the field of Alzheimer’s disease research has witnessed significant developments with the emergence of anti-amyloid drugs. These drugs target the accumulation of amyloid plaques in the brain, a hallmark feature of Alzheimer’s disease. While initial results have shown promise, it is crucial to approach these findings with a critical lens, considering both the potential benefits and controversies surrounding these treatments.

The BBC Panorama episode “Alzheimer’s: A Turning Point?” presented by BBC Medical Editor Fergus Walsh, aired on February 12th and explored the potential of two new drugs, Lecanemab and Donanemab, to significantly impact the fight against Alzheimer’s disease.

Lecanemab, developed by Biogen, has generated considerable excitement in the scientific community. Early clinical trials have suggested that Lecanemab may effectively reduce the levels of amyloid plaques in the brain, providing a glimmer of hope for people diagnosed with Alzheimer’s and their families. The drug’s potential to modify the course of the disease, rather than merely alleviating symptoms, has fuelled optimism.

However, the journey of Lecanemab has not been without its share of controversies, particularly in America. The FDA’s initial rejection of the drug, due to concerns about the robustness of the clinical trial data, raised questions about the drug’s efficacy. Subsequently, Biogen and the FDA engaged in discussions, leading to a re-evaluation of the data and an eventual approval. This turn of events has prompted scepticism within the scientific community, highlighting the need for transparency and rigorous scrutiny in drug approval processes.

Donanemab, another anti-amyloid drug developed by Eli Lilly, has also entered the spotlight. Preliminary results from clinical trials suggest that Donanemab not only reduces amyloid plaques but also demonstrates potential cognitive benefits. These findings have reignited hope for a breakthrough in Alzheimer’s treatment.

The BBC documentary followed patients with early-stage Alzheimer’s who participated in clinical trials for these drugs in the UK. An outcome of the clinical trials was that both Lecanemab and Donanemab have shown promising results in slowing down the progression of the disease, offering a glimmer of hope for a future where Alzheimer’s can be managed like chronic condition, such as diabetes. However, the programme also highlighted the challenges associated with widespread access to these drugs, even if approved.

Despite the initial promise, it is essential to acknowledge the challenges associated with anti-amyloid drugs. Some critics argue that targeting amyloid plaques might not address the root cause of Alzheimer’s disease, as other factors, such as tau protein tangles and inflammation, may also play significant roles. Additionally, the potential side effects and long-term impacts of these drugs remain uncertain, underscoring the need for ongoing research and monitoring.

In addition, the BBC Panorama episode highlighted the fact that only a small percentage (2%) of people with dementia receive the “gold standard” diagnoses needed to qualify for these treatments, which require confirmation of high amyloid levels in the brain. Dr. Susan Kohlhaas, from Alzheimer’s Research UK, emphasised the need for the NHS to prepare for potential drug rollouts, by improving access to accurate diagnoses through methods such as PET scans and lumbar punctures. Finally, these drugs are expensive, with estimated costs totalling at least £20,000 per person per year, so the big question is will the NHS approve access to these drugs with that price tag?

While Lecanemab and Donanemab show promise in the realm of Alzheimer’s research, it is crucial to maintain a cautious and balanced perspective. Continued research is necessary to fully understand the long-term effects, potential risks, and broader applicability of these drugs. Furthermore, exploring alternative approaches and combination therapies could offer a more comprehensive strategy in the fight against Alzheimer’s disease.

The BBC Panorama documentary offered a cautiously optimistic outlook on the future of Alzheimer’s treatment, presenting these new drugs as a potential “turning point” in the fight against the disease. It also acknowledged the significant hurdles that need to be overcome before these treatments can benefit a wider population.

It is important to acknowledge that the emergence of anti-amyloid drugs like Lecanemab and Donanemab marks a significant milestone in Alzheimer’s research. While the initial results are promising, it is crucial to approach these findings with a critical mindset, considering the controversies, uncertainties, and ongoing challenges associated with these treatments. Only through rigorous research, transparency and collaboration, can the scientific community hope to make meaningful strides in the pursuit of effective Alzheimer’s treatments.

BBC’s Panorama episode “Alzheimer’s: A Turning Point?” is available to watch on BBC iPlayer.

What are your thoughts on these pharmaceutical developments in Alzheimer’s research?

Categories: Dementia

Notify of

Inline Feedbacks
View all comments